Johnson & Johnson (ETR:JNJ)
Germany · Delayed Price · Currency is EUR | Market Cap | 424.82B |
| Revenue (ttm) | 78.81B |
| Net Income (ttm) | 21.48B |
| Shares Out | n/a |
| EPS (ttm) | 8.85 |
| PE Ratio | 19.78 |
| Forward PE | 18.79 |
| Dividend | 4.57 (2.60%) |
| Ex-Dividend Date | Nov 25, 2025 |
| Volume | 1,876 |
| Average Volume | 3,300 |
| Open | 176.10 |
| Previous Close | 178.28 |
| Day's Range | 174.94 - 176.26 |
| 52-Week Range | 128.16 - 183.96 |
| Beta | 0.35 |
| RSI | 51.96 |
| Earnings Date | Jan 21, 2026 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]
Financial Performance
In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.
Financial numbers in USD Financial StatementsNews
Rep. Thomas Kean Has Sold Up to $100K Worth Of Johnson & Johnson Stock: Here's What You Should Know
A December filing shows that Representative Thomas Kean reported a sale in Johnson & Johnson (NYSE: JNJ), valued between $30,002 and $100,000. The transaction date is listed as November 20, 2025, wit...
Johnson & Johnson hit with another giant asbestos-talcum powder verdict: $65.5 million in Minnesota
Jurors found for the 37-year-old plaintiff, who used J&J's baby powder throughout her childhood and later developing mesothelioma.
Why a Minnesota Jury Ordered Johnson & Johnson To Pay $65.5 Million in Damages
Johnson & Johnson (NYSE: JNJ) has been directed to pay $65.6 million to a Minnesota woman who was diagnosed with cancer following the use of their talcum powder. What Happened : A Minnesota jury awar...
Jury says Johnson & Johnson owes woman $65.5 million
Jury says Johnson & Johnson owes woman $65.5 million
Minnesota jury says Johnson & Johnson owes $65.5 million to woman with cancer who used talcum powder
A Minnesota jury awarded $65.5 million on Friday to a mother of three who claimed talcum products made by Johnson & Johnson exposed her to asbestos and contributed to her developing cancer in the lini...
Minnesota Jury Delivers $65.5 Million History-Making Verdict Against Johnson & Johnson
ST. PAUL, Minn.--(BUSINESS WIRE)--A Minnesota jury awarded $65.5 million to a 37-year-old mother of three minor children after finding in her favor in a lawsuit against Johnson & Johnson, concluding t...
JNJ Today: Goldman Sachs Raises Johnson & Johnson Price Target | JNJ Stock News
JNJ Today: Goldman Sachs Raises Johnson & Johnson Price Target | JNJ Stock News
Johnson & Johnson (JNJ) Gains FDA Approval for New Lung Cancer Treatment
Johnson & Johnson (JNJ) Gains FDA Approval for New Lung Cancer Treatment
FDA Approves J&J's New 5-Minute Injection For Lung Cancer
On Wednesday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson (NYSE: JNJ) Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), the first and only subcutaneously (SC) administ...
J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant
JNJ wins FDA approval for a subcutaneous version of Rybrevant, cutting treatment time to minutes and boosting convenience across NSCLC indications.
Noteworthy ETF Inflows: IWX, JNJ, BAC, WFC
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell Top 200 Value ETF (Symbol: IWX) where we have detected...
Johnson & Johnson (JNJ) Receives FDA Approval for Expanded Use of TRUFILL System
Johnson & Johnson (JNJ) Receives FDA Approval for Expanded Use of TRUFILL System
Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma
- TRUFILL n-BCA is now indicated for embolization of the middle meningeal artery (MMA) for the treatment of symptomatic subacute and Chronic Subdural Hematoma (cSDH) as an adjunct to surgery. - Approv...
FDA Approves Injectable Rybrevant for JNJ, Offering New NSCLC Treatment Option
FDA Approves Injectable Rybrevant for JNJ, Offering New NSCLC Treatment Option
J&J wins FDA nod for Rybrevant injectable in lung cancer
Johnson & Johnson (JNJ) stock is in focus as the FDA greenlights the company's Rybrevant injectable developed with Halozyme (HALO) for lung cancer. Read more here.
Johnson & Johnson: Valuation Premium Justified By Accelerating Growth And Mix Premiumization
Johnson & Johnson's portfolio reshaping should enhance margins and long-term growth prospects. Click here to read why JNJ stock is a Buy.
FDA Approves Johnson & Johnson's RYBREVANT FASPRO, First Subcutaneous Therapy For EGFR-Mutated NSCLC
(RTTNews) - Johnson & Johnson (JNJ) announced that the U.S. Food and Drug Administration has approved RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj), the first and only subcutaneously (SC) admi...
FDA Greenlights JNJ's Innovative Cancer Treatment: RYBREVANT FASPRO
FDA Greenlights JNJ's Innovative Cancer Treatment: RYBREVANT FASPRO
U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)
RYBREVANT FASPRO™, the first and only subcutaneous therapy for patients with EGFR-mutated NSCLC, reduces administration time from hours to minutes and significantly reduces administration-related reac...
Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Is Monte Rosa Stock Trading Higher Today?
Monte Rosa Therapeutics Inc . (NASDAQ: GLUE) shared interim data from an ongoing Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated patients with meta...
2 Recession-Proof Stocks to Watch in December
Walmart's low prices make it a go-to during recessions when people are cutting back on spending. Johnson & Johnson sells consumer health products that many people don't cut back on when adjusting thei...
Johnson & Johnson: Quality Compounding, Valuations Now Do The Heavy Lifting
Final Trade: JNJ, NVO, UBER, BMY
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
Final Trade: JNJ, NVO, UBER, BMY
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.